N/A N=308 Randomized Treatment

Effects of Open-label vs Double-blind Treatment in IBS

Irritable Bowel Syndrome · Placebo Effect · Placebos · Peppermint Oil

Bottom Line

View on ClinicalTrials.gov: NCT02802241 ↗

Enrolled (actual)

308

Serious AEs

0.0%

Results posted

Sep 2020

Primary outcome: Primary: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks. — 74.6; 94.6; 56.4; 90.8 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: placebo (Drug); peppermint oil (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Beth Israel Deaconess Medical Center
Primary completion: Jan 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks.	74.6; 94.6; 56.4; 90.8; 90.6; 100.3	—

Summary

The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.

Eligibility Criteria

Inclusion Criteria

Meet Rome IV diagnostic criteria for IBS

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02802241). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.